10-K: Arcutis Sees Strong ZORYVE Sales, Narrows Losses in 2025

Arcutis Biotherapeutics reports significant revenue growth for its ZORYVE product line in 2025, driven by expanded indications and commercial launches, despite ongoing net losses and a terminated promotion agreement.

Summary

• Arcutis Biotherapeutics, Inc. reported total revenues of $376.072 million for the year ended December 31, 2025, a substantial increase from $196.542 million in 2024.
• Net product revenue grew by 123% year-over-year, reaching $372.072 million in 2025, compared to $166.542 million in 2024.
• ZORYVE cream 0.3% generated $120.995 million in revenue, ZORYVE foam $181.892 million, ZORYVE cream 0.15% $68.274 million, and ZORYVE cream 0.05% $0.911 million in 2025.
• The company significantly reduced its net loss to $16.141 million in 2025, an improvement from a net loss of $140.039 million in 2024.
• As of December 31, 2025, the accumulated deficit was $1,138.1 million, and cash, cash equivalents, restricted cash, and marketable securities totaled $221.3 million.
• The promotion agreement with Kowa Pharmaceuticals America, Inc. was mutually terminated effective January 23, 2026, with Arcutis assuming sales and promotion responsibilities in primary care and pediatrics.
• Positive topline data from the INTEGUMENT-INFANT Phase 2 study for ZORYVE cream 0.05% in infants with atopic dermatitis was announced in February 2026, with an sNDA submission planned for Q2 2026.
• A Phase 1 study of ARQ-234, a CD200R fusion protein for atopic dermatitis, is anticipated to commence in Q1 2026.
• Development of ARQ-252 and ARQ-255 programs has been halted.
• The company is defending its patents in ongoing litigation against Padagis regarding a generic version of ZORYVE cream 0.3%, and successfully defended two European patents against Teva oppositions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting strong commercial growth and pipeline advancement, particularly with ZORYVE, and a significant reduction in net loss. However, the termination of the Kowa agreement, ongoing litigation, and broader industry regulatory pressures introduce some caution.

Positives

• Total revenues increased significantly to $376.072 million in 2025 from $196.542 million in 2024, demonstrating strong commercial growth.
• Net product revenue surged by 123% year-over-year, reaching $372.072 million in 2025, driven by increased patient demand and new product launches.
• ZORYVE cream 0.3% revenue grew 42% to $120.995 million, and ZORYVE foam revenue increased 154% to $181.892 million in 2025.
• ZORYVE cream 0.15% revenue saw a 588% increase to $68.274 million in 2025, following its successful U.S. commercial launch in July 2024.
• Net loss was substantially reduced to $16.141 million in 2025 from $140.039 million in 2024, indicating improved financial performance and a path towards profitability.
• Positive topline data from the INTEGUMENT-INFANT Phase 2 study supports a potential label expansion for ZORYVE cream 0.05% for infants as young as 3 months with atopic dermatitis.
• Health Canada approved ZORYVE cream 0.3% for plaque psoriasis in individuals down to 2 years old and ZORYVE foam 0.3% for plaque psoriasis of the scalp and body in individuals 12 years and older.
• The company plans to advance ARQ-234, a promising biologic candidate for atopic dermatitis, into a Phase 1 study in Q1 2026.
• Successfully defended two European patents against oppositions filed by Teva Pharmaceutical Industries Ltd., reinforcing intellectual property protection.
• Maintained compliance with all covenants under the Loan Agreement as of December 31, 2025, indicating sound financial management.

Negatives

• The company continues to incur net losses, with an accumulated deficit of $1,138.1 million as of December 31, 2025.
• The promotion agreement with Kowa Pharmaceuticals America, Inc. was mutually terminated effective January 23, 2026, requiring Arcutis to re-establish sales and promotion efforts in primary care and pediatrics.
• Further development of the ARQ-252 and ARQ-255 programs has been halted, representing discontinued pipeline assets.
• Interest income decreased by $7.2 million in 2025, primarily due to lower cash and marketable securities balances and reduced investment yields.
• Ongoing patent infringement litigation with Padagis regarding a generic version of ZORYVE cream 0.3% poses a risk of substantial expenses and potential market competition.
• The 30-month FDA approval stay for Padagis's ANDA was extended due to the litigation stay, prolonging uncertainty regarding generic entry.
• The company is exposed to macroeconomic factors, including inflation, interest rates, political instability, and trade disputes, which could adversely affect business operations and financial performance.
• The Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act are expected to negatively impact the pharmaceutical industry, potentially affecting the company's revenues and ability to invest in new products.
• CMS informed the company in April 2024 that it is not eligible for the phase-in of IRA manufacturer discounts, which could adversely impact future revenues.

Risks

• Significant losses since inception and limited commercial-stage history make future viability difficult to assess.
• Capital requirements are difficult to predict, and substantial additional financing may be needed, which might not be available on acceptable terms, potentially forcing delays or termination of operations.
• Operating results may fluctuate significantly, making future results difficult to predict and potentially causing them to fall below expectations.
• Estimated market opportunities may prove inaccurate, limiting future growth.
• The loan and security agreement requires meeting certain operating and financial covenants and places restrictions on operating and financial flexibility.
• Sales, marketing, and distribution of ZORYVE or any future approved products may be unsuccessful or less successful than anticipated.
• Business is dependent on the successful commercialization of ZORYVE and the development, regulatory approval, and commercialization of current product candidates.
• Even if product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payers, or others in the medical community.
• Inability to achieve and maintain third-party payer coverage and adequate levels of reimbursement for products could severely hinder commercial success.
• Clinical drug development is a lengthy, expensive, and uncertain process, with potential for additional costs or delays.
• Inability to obtain regulatory approval for label expansions or product candidates under applicable regulatory requirements.
• Topline or preliminary data from clinical trials may change, and subjective endpoints may be difficult to meet.
• Enrollment and retention of subjects in clinical trials is expensive and time-consuming, potentially causing delays or failure of development activities.
• Serious adverse or unacceptable side effects may be identified during development, preventing or delaying regulatory approval and commercialization.
• Need to increase organization size and potential difficulties in executing growth strategy, managing growth, and retaining talent.
• Inability to acquire, develop, and commercialize additional product candidates would impair business expansion and strategic objectives.
• Significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications.
• Collaboration arrangements may not be successful, adversely affecting ability to develop and commercialize future product candidates.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Reliance on third-party manufacturers and suppliers for nonclinical, clinical, and commercial supplies, with risks of loss, non-compliance, or insufficient quantities.
• Reliance on third parties to conduct nonclinical studies and clinical trials, with risks of non-performance or missed deadlines.
• Inability to obtain, maintain, or enforce patent rights or other intellectual property rights of sufficient breadth.
• Exposure to claims alleging infringement of third parties' patents or proprietary rights, or claims seeking to invalidate company patents.
• Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents.
• Failure to comply with obligations under license, collaboration, or other agreements could lead to loss of intellectual property rights.
• Inability to protect the confidentiality of proprietary information and know-how could adversely affect technology and product value.
• Extensive and ongoing regulatory obligations and continued regulatory review, with potential for significant additional expense and penalties for noncompliance.
• Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or policy changes.
• Subject to health care laws and regulations, with potential for substantial penalties for non-compliance.
• FDA and applicable foreign regulatory authorities may not accept data from clinical trials conducted outside the United States.
• Recently enacted and future legislation and regulation (e.g., ACA, IRA, One Big Beautiful Bill Act) may increase difficulty and cost of commercialization and affect prices.
• Failure to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs.
• Improper promotion for off-label uses or physician misuse of products could lead to penalties and reputational harm.
• Stock price may be volatile or decline due to numerous factors beyond control.
• Ability to utilize net operating loss carryforwards and research and development income tax credit carryforwards may be limited.
• Provisions in corporate charter documents and under Delaware law may prevent or frustrate attempts by stockholders to change management and hinder efforts to acquire a controlling interest.
• Adverse effects from earthquakes or other natural disasters.
• Changes in tax laws or regulations could have a material adverse effect.
• Future litigation could have a material adverse effect on business and results of operations.

Future Outlook

The company expects research and development expenses to increase in 2026, driven by the clinical development program for ARQ-234 and ZORYVE label expansions. Selling, general and administrative expenses are also projected to increase due to continued ZORYVE commercialization. An sNDA submission for ZORYVE cream 0.05% for infants with atopic dermatitis is intended for Q2 2026, and a Phase 1 study for ARQ-234 is anticipated to commence in Q1 2026. Management believes existing capital resources will be sufficient for at least 12 months, but acknowledges the potential need for additional financing through equity, debt, or collaborations. The company also anticipates negative impacts on the pharmaceutical industry from recent legislation like the Inflation Reduction Act and the One Big Beautiful Bill Act, which could affect revenues and investment in new products.

Management Comments

• "We believe we have built a leading platform for dermatologic product development and commercialization."
• "Our strategy is to focus on validated biological targets, and to use our drug development platform and deep dermatology expertise to develop and commercialize differentiated products that have the potential to address the major shortcomings of existing therapies in our targeted indications."
• "We believe this strategy uniquely positions us to rapidly advance our goal of bridging the treatment innovation gap in dermatology, while maximizing our probability of technical success and financial resources."
• "We believe that ZORYVE foam presents a unique dual mechanism of action to treat patients with seborrheic dermatitis."
• "We believe the acquisition of this asset [ARQ-234] is a transformative opportunity for Arcutis and, in leveraging our team's deep dermatology expertise and broad biologics experience, that our leadership and operational team will enable us to move ARQ-234 into the clinic and through the development process."
• "Our primary focus since our founding has been to address patients significant need for innovative treatments that directly target molecular mediators of disease, have the potential to show significant symptomatic improvement, maintain a low risk of toxicity or side effects, and are suitable for chronic use on all areas of the body."
• "We plan to vigorously defend our extensive intellectual property rights in ZORYVE cream 0.3%."

Industry Context

StockSavvy.ai notes that the dermatology market is highly competitive, characterized by rapid technological advancements and new product introductions from a diverse range of pharmaceutical and biotechnology companies. The significant unmet need for effective, chronic, and well-tolerated topical treatments, particularly steroid-free options, continues to drive innovation. Arcutis's focus on PDE4 inhibitors like ZORYVE addresses this gap, positioning it against both traditional topical corticosteroids (TCS) and newer non-steroidal agents like topical tapinarof (Vtama) and ruxolitinib (Opzelura), which often carry their own limitations or side effect profiles. The termination of the Kowa promotion agreement highlights the challenges in expanding market reach beyond specialized dermatologists to broader primary care and pediatric settings. The ongoing patent litigation with Padagis is a common industry dynamic, reflecting the intense competition and efforts by generic manufacturers to enter the market. Furthermore, the increasing governmental pressure on drug pricing and reimbursement, exemplified by the Inflation Reduction Act and the One Big Beautiful Bill Act, represents a significant industry-wide trend that could impact all pharmaceutical companies' revenue and investment strategies.

Comparison to Industry Standards

• ZORYVE cream offers symptomatic improvement in psoriasis and atopic dermatitis comparable to high-potency steroids, but with a favorable tolerability profile and suitability for chronic use on all body areas, addressing key limitations of traditional topical corticosteroids (TCS) which are associated with significant side effects like HPA axis suppression, skin atrophy, and are not recommended for chronic or sensitive area use.
• ZORYVE foam is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades, differentiating it from older, less effective antifungal agents and immunomodulators like TCIs which carry boxed warnings for cancer risk.
• Roflumilast, the active ingredient in ZORYVE, demonstrates a potency advantage of approximately 25x to over 300x compared to other FDA-approved PDE4 inhibitors such as crisaborole (Eucrisa, Pfizer Inc.) and apremilast (Otezla, Amgen Inc.), suggesting a potentially superior pharmacological profile.
• Unlike topical ruxolitinib (Opzelura, Incyte Corporation), which carries an extensive boxed warning for serious infections, mortality, malignancy, and cardiovascular events, and is limited to short-term, intermittent use, ZORYVE cream 0.15% and 0.05% are approved for long-term disease control in atopic dermatitis with no limitations on location, body surface area, concomitant use, or duration.
• The company's strategy to leverage validated biological targets and deep dermatology expertise aligns with industry best practices for developing differentiated products that address significant unmet needs, aiming for higher technical success and efficient resource allocation compared to broad-spectrum drug discovery approaches.
• The successful defense of two European patents against Teva Pharmaceutical Industries Ltd. oppositions demonstrates a robust intellectual property strategy, which is crucial for maintaining market exclusivity against competitors in the biopharmaceutical sector.

Legal Proceedings

• Arcutis Biotherapeutics, Inc. filed a patent infringement lawsuit against Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC in the U.S. District Court for the District of Delaware on March 27, 2024, regarding a generic version of ZORYVE cream 0.3%.
• The lawsuit asserts infringement of eleven patents listed in the FDA's Orange Book for ZORYVE cream 0.3%.
• Padagis's Paragraph IV certifications claim non-infringement, invalidity, and/or unenforceability of the asserted patents.
• The filing of the lawsuit triggered an automatic 30-month stay of FDA approval for Padagis's ANDA, originally set to expire on August 14, 2026.
• In March 2025, Arcutis agreed to a joint stipulation to stay the ongoing patent litigation with Padagis at Padagis's request, and the court stayed the case on April 3, 2025, extending the 30-month FDA approval stay for the duration of the litigation stay.
• Teva Pharmaceutical Industries Ltd. filed oppositions with the European Patent Office (EPO) against two European patents (EP 3634380 B1 and EP 3684334 B1) in the third quarter of 2024.
• After oral proceedings, the EPO panel found in favor of Arcutis and maintained both patents, though these decisions are subject to potential appeals by Teva.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises, stock price volatility influenced by commercial success and litigation outcomes, and reliance on stock price appreciation for return on investment as no dividends are planned.
• Employees: Company's growth strategy necessitates attracting and retaining highly qualified personnel, with stock-based compensation as a key incentive; potential for staff reductions if additional funding is not secured.
• Customers (Physicians, Patients, Payers): Expanded product indications and new formulations (e.g., ZORYVE cream 0.05% for infants, ZORYVE foam for scalp psoriasis) offer more treatment options; focus on steroid-free, chronic use treatments addresses unmet needs; however, challenges in obtaining third-party payer coverage and adequate reimbursement could affect product access and affordability.
• Suppliers/Manufacturers: Continued reliance on third-party contract manufacturing organizations (CMOs) and single-source suppliers introduces supply chain risks, requiring strict compliance with cGMPs.
• Creditors (SLR Investment Corp.): The company is subject to financial and operating covenants under its loan agreement, with repayment obligations and a security interest granted in substantially all company assets.

Next Steps

• Submit a supplemental New Drug Application (sNDA) to the FDA in the second quarter of 2026 for ZORYVE cream 0.05% for the treatment of infants with atopic dermatitis down to the age of 3 months.
• Anticipate commencing a Phase 1 study of ARQ-234 in the first quarter of 2026.
• Assume responsibility for sales and promotion of ZORYVE in the pediatric and primary care settings, initially through a small, targeted sales team, following the termination of the Kowa promotion agreement.
• Continue efforts to extend the breadth of the prescribing base beyond dermatologists to primary care and pediatric health care providers.
• Continue expanding insurance coverage for ZORYVE, particularly in Medicare and Medicaid.
• Evaluate additional inflammatory dermatoses for ZORYVE expansion through resource-efficient Phase 2 proof-of-concept trials (e.g., hidradenitis suppurativa and vitiligo).
• Continue to evaluate strategic opportunities to in-license or acquire select dermatology and inflammation and immunology (I&I) assets.
• Vigorously defend extensive intellectual property rights in ZORYVE cream 0.3% against generic challenges, including the ongoing litigation with Padagis.
• Manage compliance with evolving healthcare laws and regulations, including the Inflation Reduction Act and the One Big Beautiful Bill Act, which may impact pricing and reimbursement.

Key Dates

Recommendation

Arcutis demonstrates strong commercial momentum with its ZORYVE franchise, achieving significant revenue growth and a substantial reduction in net losses in 2025. The expansion of ZORYVE's indications and positive clinical data for new pediatric uses are positive catalysts. However, the termination of the Kowa promotion agreement, ongoing patent litigation with Padagis, and the inherent risks of biopharmaceutical development, including the need for future financing and the impact of healthcare reform, present considerable uncertainties. The stock's performance has been volatile, and while the company is moving towards profitability, these factors suggest a 'hold' position until there is clearer resolution on the litigation, successful integration of direct sales efforts, and further de-risking of the pipeline.

Keywords

Biopharmaceutical, Dermatology, ZORYVE, Roflumilast, Plaque Psoriasis, Atopic Dermatitis, Seborrheic Dermatitis, PDE4 inhibitor, ARQ-234, CD200R, Clinical Trials, FDA Approval, Commercialization, Patent Litigation, Drug Development, Immunodermatology, Topical Treatment, Biologics